Species distribution and antifungal susceptibility of Candida spp. isolated from superficial candidiasis in outpatients in Iran

Razzaghi-Abyaneh, Mehdi; Sadeghi, Golnar; Zeinali, Elham; Alirezaee, M.; Shams-Ghahfarokhi, Masoomeh; Amani, Akram; Mirahmadi, R; Tolouei, R.

doi:10.1016/j.mycmed.2014.01.004

Cited by 36 publications

(25 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In Latin America, C. parapsilosis was followed by C. albicans and C. glabrata was the fourth ( 17 ). By contrast, the prevalence of C. glabrata infections was reported to be low in Iran ( 18 ).…”

Section: Discussionmentioning

confidence: 99%

In Vitro Activities of Six Antifungal Drugs Against Candida glabrata Isolates: An Emerging Pathogen

Amirrajab

Badali

Didehdar

et al. 2016

Jundishapur J Microbiol

View full text Add to dashboard Cite

BackgroundCandida glabrata is a pathogenic yeast with several unique biological features and associated with an increased incidence rate of candidiasis. It exhibits a great degree of variation in its pathogenicity and antifungal susceptibility.ObjectivesThe aim of the present study was to evaluate the in vitro antifungal susceptibilities of the following six antifungal drugs against clinical C. glabrata strains: amphotericin B (AmB), ketoconazole (KTZ), fluconazole (FCZ), itraconazole (ITZ), voriconazole (VCZ), and caspofungin (CASP).Materials and MethodsForty clinical C. glabrata strains were investigated using DNA sequencing. The in vitro antifungal susceptibility was determined as described in clinical laboratory standard institute (CLSI) documents (M27-A3 and M27-S4).ResultsThe sequence analysis of the isolate confirmed as C. glabrata and deposited on NCBI GenBank under the accession number no. KT763084-KT763123. The geometric mean MICs against all the tested strains were as follows, in increasing order: CASP (0.17 g/mL), VCZ (0.67 g/mL), AmB (1.1 g/mL), ITZ (1.82 g/mL), KTZ (1.85 g/mL), and FCZ (6.7 g/mL). The resistance rates of the isolates to CASP, FCZ, ITZ, VZ, KTZ, and AmB were 5%, 10%, 72.5%, 37.5%, 47.5%, and 27.5%, respectively.ConclusionsThese findings confirm that CASP, compared to the other antifungals, is the potent agent for treating candidiasis caused by C. glabrata. However, the clinical efficacy of these novel antifungals remains to be determined.

show abstract

Section: Discussionmentioning

confidence: 99%

In Vitro Activities of Six Antifungal Drugs Against Candida glabrata Isolates: An Emerging Pathogen

Amirrajab

Badali

Didehdar

et al. 2016

Jundishapur J Microbiol

View full text Add to dashboard Cite

show abstract

“…In the last two decades, fungal infections have shown a significant increment. In addition to the increase in the number of patients with compromised immune system, factors such as increasing number of patients using catheters, the use of broad-spectrum antibiotics, the rising number of patients requiring organ transplantations, as well as those with hematological malignancies and diabetes also contribute to this phenomenon [26,27].…”

Section: Pathogenic Yeast Infections: a Serious Health Problemmentioning

confidence: 99%

Phytochemicals and Their Antifungal Potential against Pathogenic Yeasts

Monteiro¹,

Santos²

2020

Phytochemicals in Human Health

View full text Add to dashboard Cite

The rate of fungal infections is increasing rapidly, and pathogenesis of their species is poorly understood. Among fungi, Candida species are a major cause of morbidity and mortality worldwide and thus represent a serious threat to public health. In addition, Cryptococcus spp. are yeasts responsible for serious lung infections and meningitis. Polyenes, fluoropyrimidines, echinocandins, and azoles are used as commercial antifungal agents to treat fungal infections. However, the presence of intrinsic and developed resistance against azole antifungals has been extensively documented. The re-emergence of classical fungal diseases has occurred because of the increment of the antifungal resistance phenomenon. In this way, the development of new satisfactory therapy for fungal diseases persists as a major challenge of present-day medicine. The urgent need includes the development of alternative drugs that are more efficient and tolerant than those traditional already in use. The identification of new substances with potential antifungal effect at low concentrations or in combination is also a possibility. This chapter briefly examines the infections caused by Candida and Cryptococcus species and focuses on describing some of the promising alternative molecules and/or substances that could be used as antifungal agents, their mechanisms of action, and their use in combination with traditional drugs.

show abstract

“…Moreover, this species represents frequent cause of onychomycosis in several countries, including Brazil (4) , Chile (16) , México (17) , and Iran (18) . Although all 87 isolates of C. parapsilosis studied in our work have been identifi ed by phenotypic methods, we were not able to differentiate among the C. parapsilosis complex species, which are phenotypically identical.…”

Section: In Vitro Susceptibility Testingmentioning

confidence: 99%

Molecular identification and antifungal susceptibility profiles of Candida parapsilosis complex species isolated from culture collection of clinical samples

Ataídes

Costa

Souza

et al. 2015

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

Introduction:Candida parapsilosis is a common yeast species found in cases of onychomycosis and candidemia associated with infected intravascular devices. In this study, we differentiated Candida parapsilosis sensu stricto, Candida orthopsilosis, and Candida metapsilosis from a culture collection containing blood and subungual scraping samples. Furthermore, we assessed the in vitro antifungal susceptibility of these species to fl uconazole, itraconazole, voriconazole, posaconazole, amphotericin B, and caspofungin. Methods: Differentiation of C. parapsilosis complex species was performed by amplifi cation of the secondary alcohol dehydrogenase (SADH) gene and digestion by the restriction enzyme BanI. All isolates were evaluated for the determination of minimal inhibitory concentrations using Etest, a method for antifungal susceptibility testing. Results: Among the 87 isolates, 78 (89.7%) were identifi ed as C. parapsilosis sensu stricto, fi ve (5.7%) were identifi ed as C. orthopsilosis, and four (4.6%) were identifi ed as C. metapsilosis. Analysis of antifungal susceptibility showed that C. parapsilosis sensu stricto isolates were less susceptible to amphotericin B and itraconazole. One C. parapsilosis sensu stricto isolate was resistant to amphotericin B and itraconazole. Moreover, 10.2% of C. parapsilosis sensu stricto isolates were resistant to caspofungin. Two C. parapsilosis sensu stricto isolates and one C. metapsilosis isolate were susceptible to fl uconazole in a dose-dependent manner. Conclusions: We reported the fi rst molecular identifi cation of C. parapsilosis complex species in State of Goiás, Brazil. Additionally, we showed that although the three species exhibited differences in antifungal susceptibility profi les, the primary susceptibility of this species was to caspofungin.

show abstract

Species distribution and antifungal susceptibility of Candida spp. isolated from superficial candidiasis in outpatients in Iran

Cited by 36 publications

References 27 publications

In Vitro Activities of Six Antifungal Drugs Against Candida glabrata Isolates: An Emerging Pathogen

In Vitro Activities of Six Antifungal Drugs Against Candida glabrata Isolates: An Emerging Pathogen

Phytochemicals and Their Antifungal Potential against Pathogenic Yeasts

Molecular identification and antifungal susceptibility profiles of Candida parapsilosis complex species isolated from culture collection of clinical samples

Contact Info

Product

Resources

About